1999
The effects of naltrexone maintenance on the response to yohimbine in healthy volunteers
Rosen M, Kosten T, Kreek M. The effects of naltrexone maintenance on the response to yohimbine in healthy volunteers. Biological Psychiatry 1999, 45: 1636-1645. PMID: 10376126, DOI: 10.1016/s0006-3223(98)00259-5.Peer-Reviewed Original ResearchConceptsWeeks of treatmentDrug effectsStrongest drug effectsOpioid antagonist naltrexoneActive naltrexoneNaltrexone treatmentNaltrexone maintenanceAntagonist naltrexoneHealthy subjectsHealthy volunteersWeek 1Week 2Cortisol levelsYohimbineWeek 5PlaceboPreclinical researchNaltrexoneAlters sensitivityEffect of pretreatmentWeeksAntagonistTreatmentStress responsivenessSubjects
1997
Treatment of Early AIDS Dementia in Intravenous Drug Users: High Versus Low Dose Peptide T
Kosten T, Rosen M, McMahon T, Bridge T, O'malley S, Pearsall R, O'connor P. Treatment of Early AIDS Dementia in Intravenous Drug Users: High Versus Low Dose Peptide T. The American Journal Of Drug And Alcohol Abuse 1997, 23: 543-553. PMID: 9366972, DOI: 10.3109/00952999709016894.Peer-Reviewed Original Research
1993
Carbamazepine vs. Oxazepam for Benzodiazepine Detoxification in Methadone‐Maintained Patients
Rosen M, Pearsall H, Price L, McDougle C, Woods S, Kosten T. Carbamazepine vs. Oxazepam for Benzodiazepine Detoxification in Methadone‐Maintained Patients. American Journal On Addictions 1993, 2: 165-168. DOI: 10.1111/j.1521-0391.1993.tb00217.x.Peer-Reviewed Original Research
1992
Peptide T Treatment of Cognitive Impairment in HIV‐Positive Intravenous Drug Users
Rosen M, Bridge T, O'Malley S, Pearsall H, Martini B, O'Connor P, Brett‐Smith H, Thomas H, Van Dyck C, Woods S, Kosten T. Peptide T Treatment of Cognitive Impairment in HIV‐Positive Intravenous Drug Users. American Journal On Addictions 1992, 1: 332-338. DOI: 10.1111/j.1521-0391.1992.tb00359.x.Peer-Reviewed Original ResearchHIV-positive intravenous drug usersDouble-blind crossover studyPeptide T treatmentHIV-positive patientsPeptide TOpen clinical trialIntravenous drug usersVasoactive intestinal peptideAIDS dementiaCrossover studyNeuropsychological improvementAZT treatmentIntestinal peptideClinical trialsDrug usersCognitive impairmentPatientsNeuropsychological functionCognitive functionT treatmentPlaceboThree timesWeeksPotential utilityTreatment